Association between Benign Prostate Hyperplasia and Prostatitis as risk predictors of Prostate Cancer
Principal Investigator
Name
Omar Catano
Degrees
M.D
Institution
The University of Texas Health Science Center at San Antonio
Position Title
Senior Research Scientist
Email
About this CDAS Project
Study
PLCO
(Learn more about this study)
Project ID
PLCO-956
Initial CDAS Request Approval
Mar 30, 2022
Title
Association between Benign Prostate Hyperplasia and Prostatitis as risk predictors of Prostate Cancer
Summary
Prostate cancer is one of most common types of cancer in the United States and one of the leading causes of mortality due to cancer. Benign Prostate Hyperplasia (BPH) and prostatitis are common affections of the urinary tract and are not considered precursors of Prostate Carcinoma. There is not a common pathological pathway linking these conditions and there are differ in their histopathological characteristics and cellular origin.
BPH and Prostate Cancer share several risk factors including older age, race, and several traits such as prostate inflammation, metabolic disruption, androgen-dependent growth, and response to antiandrogen therapy. More than 80% of cases of Prostate cancer occur in men with history of BPH.
Although studies looking for associations among these conditions have reported mixed results, evidence of positive associations in selected groups including differences by race, socio-economic status and access to healthcare services have been described.
History of clinical chronic prostatitis associates with risk of prostate carcinoma in the general population but not in selected groups such as in African Americans.
We are interested in examining the association between BPH and prostatitis as independent risk factors of prostate carcinoma in the PLCO cohort as a whole as well as in selected groups.
BPH and Prostate Cancer share several risk factors including older age, race, and several traits such as prostate inflammation, metabolic disruption, androgen-dependent growth, and response to antiandrogen therapy. More than 80% of cases of Prostate cancer occur in men with history of BPH.
Although studies looking for associations among these conditions have reported mixed results, evidence of positive associations in selected groups including differences by race, socio-economic status and access to healthcare services have been described.
History of clinical chronic prostatitis associates with risk of prostate carcinoma in the general population but not in selected groups such as in African Americans.
We are interested in examining the association between BPH and prostatitis as independent risk factors of prostate carcinoma in the PLCO cohort as a whole as well as in selected groups.
Aims
• Determine the association between BPH and prostatitis with Prostate carcinoma and response to therapy
• Assess the role of race in the strength of the association between BPH and prostatitis with Prostate carcinoma.
• Find a prediction model that include benign prostate clinical conditions with the risk of prostate carcinoma in selected population groups.
• Identify potential actionable factors that decrease the incidence and increase therapeutic success in prostate carcinoma in at-risk populations.
Collaborators
Pratap A. Kumar (The University of Texas Health Science Center at San Antonio)